Condition (MeSH)
Neoplasms, Gonadal Tissue
ClinicalTrials.gov lists 16 trials for Neoplasms, Gonadal Tissue or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Neoplasms, Gonadal Tissue trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2012 | 3 |
| 2011 | 1 |
| 2010 | 2 |
| 2008 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasms, Gonadal Tissue trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Not applicable | 2 |
| Observational | 5 |
How many Neoplasms, Gonadal Tissue trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 8 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasms, Gonadal Tissue trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 1 |
| GOG Foundation | 1 |
| Gynecologic Oncology Group | 1 |
| National Cancer Institute (NCI) | 1 |
Which drugs are being tested for Neoplasms, Gonadal Tissue? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 2 |
| FULVESTRANT | 1 |
| NIVOLUMAB | 1 |
| Bleomycin | 1 |
| TAK-700 | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 2 |
| Gemcitabine/Gemzar | 1 |
| Cisplatin 1 | 1 |
| Stereotactic Body Radiation Therapy | 1 |
| Etoposid | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neoplasms, Gonadal Tissue trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil Count Decreased | 12 | 1 |
| Hyperglycemia | 4 | 3 |
| Obstruction, Gi - Small Bowel Nos | 3 | 1 |
| Constipation | 2 | 1 |
| Febrile Neutropenia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Neoplasms, Gonadal Tissue? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. | Kidney international | 2004 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.